This article is more than 5 years old. Information may no longer be current.

Research collaboration announced between MedImmune, Joslin Diabetes Center

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A 3-year research collaboration between MedImmune and Joslin Diabetes Center to develop new medicines for the treatment for diabetes, obesity and related metabolic disorders was recently announced, according to a press release.

Several key areas of focus have been identified as initial projects to identify new drug candidates, including protecting and regenerating the insulin-producing beta cells, increasing the caloric utilization of fat depots and replicating the beneficial effects of bariatric surgery pharmacologically.

“Cardiovascular and metabolic disease is a main therapy area for MedImmune, and we are pleased to enter this new research partnership with Joslin Diabetes Center to identify and translate the most promising emerging science into novel drug development projects with the potential to help patients suffering with diabetes, obesity and other metabolic diseases,” Cristina Rondinone, vice president and head of MedImmune’s cardiovascular and metabolic disease innovative medicines unit, said in the release. “Joslin Diabetes Center is world renowned for metabolic disease research and will be an important partner for MedImmune and AstraZeneca as we continue our commitment to improve diabetes management and care through the development of innovative medicines.”

Funding to Joslin will be provided by MedImmune to help bring drug development expertise and capabilities in combination with Joslin’s early metabolic disease research and clinical care infrastructure. License development and commercial rights to projects emerging from the collaboration will be given to MedImmune as an option.

“This partnership combines the discovery research and clinical care expertise at Joslin with MedImmune’s great development capabilities to hopefully move these projects from important new concepts to treatments that could benefit the patients we treat in our clinic and the millions of others like them across the globe suffering from metabolic diseases,” C. Ronald Kahn, MD, chief academic officer of Joslin Diabetes Center, said in the release.